Gene:
AGT
angiotensinogen (serpin peptidase inhibitor, clade A, member 8)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs4762 230845977G>A, 24363756G>A, 620C>T, 9360C>T, AGT:Thr174Met, Thr207Met, angiotensinogen T174M
G > A
Missense
Thr207Met
No VIP available No Clinical Annotations available VA
rs5050 -58A>C, 230849886T>G, 24367665T>G, 5451A>C
T > G
5' UTR
No VIP available CA VA
rs5051 -44G>A, 230849872C>T, 24367651C>T, 5465G>A, AGT G(-6)A
C > T
5' UTR
No VIP available CA VA
rs699 230845794A>G, 24363573A>G, 803T>C, 9543T>C, AGT M235T, AGT Met235Thr, AGT:Met235Thr, angiotensinogen M235T
A > G
Missense
Met268Thr
No VIP available CA VA
rs7079 *556C>A, 17006C>A, 230838331G>T, 24356110G>T
G > T
3' UTR
No VIP available CA VA
rs943580 18293C>T, 230837044G>A, 24354823G>A
G > A
Not Available
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  SERPINA8; alpha-1 antiproteinase, antitrypsin
Alternate Symbols:  None
PharmGKB Accession Id: PA42

Details

Cytogenetic Location: chr1 : q42.2 - q42.2
GP mRNA Boundary: chr1 : 230838269 - 230850336
GP Gene Boundary: chr1 : 230835269 - 230860336
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. ACE Inhibitor Pathway, Pharmacodynamics
    Model, non-tissue-specific cell displaying genes which may be involved in the ACE inhibitor pathway
  1. Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics
    Genes involved in the pharmacodynamics of the drugs that act on the renin-angiotensin-aldosterone system.
  1. Glucocorticoid Pathway - Transcription Regulation, Pharmacodynamics
    Model displaying genes which may be involved in the nuclear complex formed that regulates transcription in response to glucocorticoids.

External Pathways

Links to non-PharmGKB pathways.

  1. activation of camp-dependent protein kinase pka - (BioCarta via Pathway Interaction Database)
  2. activation of csk by camp-dependent protein kinase inhibits signaling through the t cell receptor - (BioCarta via Pathway Interaction Database)
  3. activation of pkc through g-protein coupled receptors - (BioCarta via Pathway Interaction Database)
  4. angiotensin ii mediated activation of jnk pathway via pyk2 dependent signaling - (BioCarta via Pathway Interaction Database)
  5. bioactive peptide induced signaling pathway - (BioCarta via Pathway Interaction Database)
  6. chrebp regulation by carbohydrates and camp - (BioCarta via Pathway Interaction Database)
  7. corticosteroids and cardioprotection - (BioCarta via Pathway Interaction Database)
  8. cystic fibrosis transmembrane conductance regulator (cftr) and beta 2 adrenergic receptor (b2ar) pathway - (BioCarta via Pathway Interaction Database)
  9. g-protein signaling through tubby proteins - (BioCarta via Pathway Interaction Database)
  10. ion channels and their functional role in vascular endothelium - (BioCarta via Pathway Interaction Database)
  11. Peptide ligand-binding receptors - (Reactome via Pathway Interaction Database)
  12. role of egf receptor transactivation by gpcrs in cardiac hypertrophy - (BioCarta via Pathway Interaction Database)
  13. role of ß-arrestins in the activation and targeting of map kinases - (BioCarta via Pathway Interaction Database)
  14. roles of ß arrestin dependent recruitment of src kinases in gpcr signaling - (BioCarta via Pathway Interaction Database)
  15. Signaling events mediated by PRL - (Pathway Interaction Database NCI-Nature Curated)
  16. ß-arrestins in gpcr desensitization - (BioCarta via Pathway Interaction Database)

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
REN

Curated Information ?

Curated Information ?

Publications related to AGT: 32

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human pharmacogenomic variation of antihypertensive drugs: from population genetics to personalized medicine. Pharmacogenomics. 2014. Polimanti Renato, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Resequencing candidate genes implicates rare variants in asthma susceptibility. American journal of human genetics. 2012. Torgerson Dara G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms, hypertension and thiazide diuretics. Pharmacogenomics. 2011. Citterio Lorena, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation in renin predicts the effects of thiazide diuretics. European journal of clinical investigation. 2011. Huang Chin-Chou, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of Hypertension Drug Target Genes With Blood Pressure and Hypertension in 86 588 Individuals. Hypertension. 2011. Johnson Andrew D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Interactions of renin-angiotensin system gene polymorphisms and antihypertensive effect of benazepril in Chinese population. Pharmacogenomics. 2011. Chen Qing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Renin-angiotensin system associated with risk of upper GI mucosal injury induced by low dose aspirin: renin angiotensin system genes' polymorphism. Digestive diseases and sciences. 2011. Shiotani Akiko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit. Pharmacogenomics. 2010. Brugts Jasper J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-inflammatory drugs. The American journal of cardiology. 2010. St Germaine Christine G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure. The pharmacogenomics journal. 2010. Wu C-K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. 2009. Brugts J J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of renin-angiotensin system polymorphisms on renal haemodynamic responsiveness to acute angiotensin-converting enzyme inhibition in type 2 diabetes mellitus. Journal of the renin-angiotensin-aldosterone system : JRAAS. 2009. Volkan-Salanci Bilge, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Renin-angiotensin system and alpha-adducin gene polymorphisms and their relation to responses to antihypertensive drugs: results from the GENRES study. American journal of hypertension. 2009. Suonsyrjä Timo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population. Pharmacogenetics and genomics. 2008. Ravn Lasse S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of renin-angiotensin-aldosterone system gene polymorphisms on blood pressure response to antihypertensive treatment. Chinese medical journal. 2007. Jiang Xiao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers. European journal of human genetics : EJHG. 2007. Schelleman Hedi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?. Expert opinion on pharmacotherapy. 2007. Athyros Vasilios G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation. 2007. Su Xiaowen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The influence of the alpha-adducin G460W polymorphism and angiotensinogen M235T polymorphism on antihypertensive medication and blood pressure. European journal of human genetics : EJHG. 2006. Schelleman Hedi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension. The American journal of gastroenterology. 2005. Sookoian Silvia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment. Journal of hypertension. 2004. Liljedahl Ulrika, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The thiazide-sensitive Na(+)-Cl(-) cotransporter gene, C1784T, and adrenergic receptor-beta3 gene, T727C, may be gene polymorphisms susceptible to the antihypertensive effect of thiazide diuretics. Hypertension research : official journal of the Japanese Society of Hypertension. 2004. Matayoshi Tetsutaro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. American journal of hypertension. 2004. Kurland Lisa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients. American journal of hypertension. 2003. Bis Joshua C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antihypertensive drug responses. American journal of pharmacogenomics : genomics-related research in drug development and clinical practice. 2004. Schwartz Gary L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic. The pharmacogenomics journal. 2004. Frazier L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of angiotensinogen M253T gene polymorphism and an angiotensin converting enzyme inhibitor on restenosis after percutaneous coronary intervention. Atherosclerosis. 2002. Toyofyuku Mamoru, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. Journal of hypertension. 2001. Kurland L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension. American journal of hypertension. 1998. Mondorf U F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. Journal of hypertension. 1996. Dudley C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanisms for inducible control of angiotensinogen gene transcription. Hypertension. 1996. Brasier A R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. Journal of hypertension. 1995. Hingorani A D, et al. PubMed

LinkOuts

Entrez Gene:
183
OMIM:
106150
145500
267430
UCSC Genome Browser:
NM_000029
RefSeq RNA:
NM_000029
RefSeq Protein:
NP_000020
RefSeq DNA:
AC_000044
AC_000133
NC_000001
NG_008836
NT_167186
NW_001838549
NW_927128
HuGE:
AGT
Comparative Toxicogenomics Database:
183
ModBase:
P01019
HumanCyc Gene:
HS06056
HGNC:
333

Common Searches